DGAP-News

MOLOGEN AG: Patient enrollment completed for IMPULSE study with immunotherapy MGN1703 in lung cancer (news with additional features)

DGAP-News: MOLOGEN AG / Key word(s): Study results/Study
MOLOGEN AG: Patient enrollment completed for IMPULSE study with
immunotherapy MGN1703 in lung cancer (news with additional features)

30.10.2015 / 13:36

---------------------------------------------------------------------

PRESS RELEASE N 17 / 2015 of 10/30/2015

MOLOGEN AG: Patient enrollment completed for IMPULSE study with
immunotherapy MGN1703 in lung cancer

Berlin, 30 October, 2015 - The biotechnology company MOLOGEN AG (ISIN
DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) has achieved
the recruitment goal with the inclusion of currently 101 patients for the
IMPULSE clinical study in lung cancer. With this trial, the company aims to
explore the potential of MGN1703 in an indication with high unmet medical
need. The randomized study is designed to evaluate efficacy and safety of
MGN1703 in patients with extensive disease small cell lung cancer. With the
finalization of recruitment, the company reached another milestone in the
clinical study program of its main product, the cancer immunotherapy
MGN1703.

The multinational randomized and controlled IMPULSE trial started at the
end of March 2014 and evaluates the efficacy and safety of MGN1703 for the
treatment of extensive disease small cell lung cancer. Primary endpoint is
overall survival, the strongest possible endpoint that can be applied in
cancer studies. Pre-defined biomarkers are used in this study and may help
to identify those patients who will benefit the most from the treatment
with MGN1703. In Germany, the trial is being conducted in collaboration
with the "Aktion Bronchialkarzinom e.V." (ABC group) - a renowned German
oncologist's network of lung cancer specialists. MOLOGEN plans to start the
analysis by the end of 2016 and present results at the Annual Meeting of
the American Society of Clinical Oncology 2017 (ASCO).

"Lung cancer and especially small cell lung cancer is a cancer indication
for which the benefit of standard treatment is currently very limited. We
are pleased that we finalized patient enrolment within the timeframe
envisaged and we are very excited to learn about the effect of MGN1703 in
this disease", said Dr. Matthias Schroff, CEO of MOLOGEN AG.

The immunotherapy MGN1703 is currently investigated in three clinical
trials. Further to the IMPULSE study, MGN1703 is being tested in the
pivotal IMPALA study for first-line maintenance treatment of metastatic
colorectal cancer (mCRC); recruitment for this trial is currently open.